ENOV - Enovis Corporation Stock Price, Fair Value and News

52.45USD+0.25 (+0.48%)Market Closed

Market Summary

USD52.45+0.25

Market Closed

0.48%

ENOV Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

ENOV Stock Price

View Fullscreen

ENOV RSI Chart

ENOV Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-35.12

Price/Sales (Trailing)

1.58

EV/EBITDA

46.28

Price/Free Cashflow

-77.06

ENOV Price/Sales (Trailing)

ENOV Profitability

EBT Margin

-6.41%

Return on Equity

-2.47%

Return on Assets

-1.5%

Free Cashflow Yield

-1.3%

ENOV Fundamentals

ENOV Revenue

Revenue (TTM)

1.8B

Rev. Growth (Yr)

27.11%

Rev. Growth (Qtr)

13.46%

ENOV Earnings

Earnings (TTM)

-81.9M

Earnings Growth (Yr)

-210.9%

Earnings Growth (Qtr)

-2.7K%

Breaking Down ENOV Revenue

Last 7 days

2.7%

Last 30 days

-6.7%

Last 90 days

-11.5%

Trailing 12 Months

-4.8%

How does ENOV drawdown profile look like?

ENOV Financial Health

Current Ratio

2.1

Debt/Equity

0.4

Debt/Cashflow

0.07

ENOV Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-1.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.8B	0	0	0
2023	1.6B	1.6B	1.7B	1.7B
2022	1.5B	1.5B	1.6B	1.6B
2021	2.6B	2.3B	1.9B	1.4B
2020	3.5B	3.2B	3.1B	3.1B
2019	2.3B	2.7B	3.0B	3.3B
2018	3.1B	2.8B	2.5B	2.2B
2017	3.2B	3.2B	3.2B	3.3B
2016	3.8B	3.6B	3.4B	3.2B
2015	4.5B	4.3B	4.1B	4.0B
2014	4.3B	4.4B	4.6B	4.6B
2013	4.0B	4.0B	4.1B	4.2B
2012	1.4B	2.3B	3.1B	3.9B
2011	580.6M	644.4M	682.3M	693.4M
2010	0	530.7M	536.3M	542.0M
2009	0	0	0	525.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enovis Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	lalor angela s	acquired	-	-	361	-
Mar 06, 2024	lang patricia a	sold (taxes)	-44,401	61.84	-718	svp, chief hr officer
Mar 06, 2024	shirley brady	sold (taxes)	-125,102	61.84	-2,023	pres. & coo
Mar 06, 2024	trerotola matthew l.	sold (taxes)	-380,749	61.84	-6,157	ceo
Mar 06, 2024	tandy bradley j	sold (taxes)	-48,049	61.84	-777	svp and chief legal officer
Mar 06, 2024	pryor daniel a	sold (taxes)	-106,860	61.84	-1,728	evp, strategy & business dev.
Mar 04, 2024	berry phillip benjamin (ben)	acquired	-	-	16,534	svp, chief financial officer
Mar 04, 2024	pryor daniel a	acquired	-	-	16,121	evp, strategy & business dev.
Mar 04, 2024	ross terry d	acquired	-	-	6,200	group president, p&r
Mar 04, 2024	lang patricia a	acquired	-	-	9,507	svp, chief hr officer

Which funds bought or sold ENOV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Ancora Advisors LLC	added	8.06	1,071,250	6,307,390	0.14%
May 16, 2024	COMERICA BANK	reduced	-4.74	186,161	3,192,440	0.01%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-55.58	-1,307,100	1,281,970	-%
May 16, 2024	Pineridge Advisors LLC	sold off	-100	-616	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.58	154,310	3,091,780	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	2.01	1,168,970	9,691,240	0.01%
May 15, 2024	Point72 Asset Management, L.P.	sold off	-100	-6,347,070	-	-%
May 15, 2024	Man Group plc	added	159	992,622	1,517,470	-%
May 15, 2024	Petrus Trust Company, LTA	reduced	-22.32	-90,144	582,096	0.05%
May 15, 2024	Royal Bank of Canada	reduced	-25.31	-243,000	1,203,000	-%

Are Funds Buying or Selling ENOV?

Are funds buying ENOV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENOV

No. of Funds

Unveiling Enovis Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.5%	5,779,368	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	12.1%	6,582,110	SC 13G/A
Feb 13, 2024	vanguard group inc	8.98%	4,900,608	SC 13G/A
Feb 12, 2024	durable capital partners lp	0%	0	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	5.8%	3,193,741	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	5,331,217	SC 13G/A
Dec 06, 2023	blackrock inc.	10.0%	5,498,552	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	11.2%	6,040,170	SC 13G/A
Feb 13, 2023	rales mitchell p	3.3%	1,798,851	SC 13G/A
Feb 13, 2023	durable capital partners lp	5.0%	2,714,032	SC 13G/A

Recent SEC filings of Enovis Corporation

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 01, 2024	4	Insider Trading
Mar 25, 2024	PRE 14A	PRE 14A
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Enovis Corporation News

Latest updates

Enovis Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	13.5%	516	455	418	429	406	409	384	395	375	399	360	356	311	828	806	620	816	888	847	909	684
Gross Profit	12.7%	298	264	243	248	235	232	216	216	206	208	198	201	171	355	344	241	348	396	368	376	261
S&GA Expenses	21.2%	256	211	204	208	207	209	182	194	188	86.00	168	198	306	-290	278	236	292	286	291	308	248
R&D Expenses	27.6%	23.00	18.00	20.00	19.00	18.00	15.00	16.00	16.00	15.00	15.00	12.00	11.00	-	-	-	-	-	-	-	-	-
EBITDA Margin	-50.6%	0.05*	0.10*	0.09*	0.06*	0.15*	0.15*	0.12*	0.18*	0.08*	0.15*	0.05*	0.07*	0.08*	-	-	-	-	-	-	-	-
Interest Expenses	370.2%	20.00	4.00	6.00	4.00	6.00	6.00	6.00	5.00	7.00	0.00	4.00	6.00	26.00	-25.82	26.00	28.00	25.00	33.00	32.00	33.00	22.00
Income Taxes	-261.3%	-7.40	5.00	-6.05	-4.71	-7.11	52.00	-12.33	-4.21	0.00	-13.41	-6.70	-3.78	8.00	-47.20	20.00	-30.06	13.00	25.00	-1.35	6.00	2.00
Earnings Before Taxes	-1134.9%	-79.24	8.00	-25.50	-19.32	-29.96	-2.54	-78.28	116	-37.69	-57.93	-20.23	-45.91	36.00	-144	36.00	-33.20	22.00	59.00	2.00	8.00	-19.49
EBT Margin	-62.9%	-0.06*	-0.04*	-0.05*	-0.08*	0.00*	0.00*	-0.04*	0.00*	-0.11*	-0.06*	-0.09*	-0.05*	-0.04*	-	-	-	-	-	-	-	-
Net Income	-2692.7%	-72.00	3.00	-2.88	-9.81	-23.16	-39.28	-66.61	77.00	16.00	-3.02	26.00	30.00	20.00	31.00	14.00	-8.05	6.00	34.00	13.00	-466	-48.00
Net Income Margin	-132.7%	-0.05*	-0.02*	-0.05*	-0.09*	-0.03*	-0.01*	0.02*	0.08*	0.05*	0.05*	0.06*	0.04*	0.02*	-	-	-	-	-	-	-	-
Free Cashflow	-280.6%	-73.08	40.00	4.00	-8.70	-22.99	-72.74	-1.46	-48.60	-38.51	66.00	68.00	58.00	60.00	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	21.5%	5,479	4,509	4,401	4,444	4,300	4,273	4,445	4,504	8,484	8,516	7,972	7,559	8,067	7,352	7,154	7,123	7,456	7,387	9,591	9,899	10,502
Current Assets	28.4%	1,151	897	854	887	833	795	1,008	1,078	2,348	2,303	1,726	1,479	2,078	1,362	1,288	1,228	1,582	1,404	3,499	3,637	2,409
Cash Equivalents	83.1%	66.00	36.00	32.00	32.00	22.00	24.00	55.00	96.00	662	680	177	62.00	764	97.00	66.00	66.00	366	110	127	132	242
Inventory	25.0%	586	469	471	454	439	427	417	401	853	356	781	664	606	565	536	557	562	572	584	595	740
Net PPE	27.7%	346	271	260	261	246	237	225	227	505	235	511	480	479	487	464	469	468	491	479	489	648
Goodwill	17.2%	2,415	2,061	36.00	2,034	1,987	1,984	36.00	1,925	3,441	1,934	3,497	3,399	3,332	1,761	3,245	3,210	3,191	3,203	2,784	2,822	3,852
Liabilities	99.1%	2,168	1,089	959	993	854	823	1,037	1,012	3,840	3,854	3,342	3,208	3,776	3,764	3,697	3,727	4,118	3,897	6,458	6,643	6,761
Current Liabilities	48.6%	549	370	355	354	349	565	854	813	1,450	1,024	975	899	1,558	812	785	759	819	857	1,506	1,599	1,572
Long Term Debt	182.8%	1,318	466	395	400	285	40.00	-	-	1,648	2,079	1,612	1,577	1,482	2,204	2,192	2,221	2,513	2,284	4,002	4,078	4,037
LT Debt, Current	-	20.00	-	-	-	-	219	449	449	422	8.00	14.00	20.00	727	27.00	27.00	27.00	27.00	28.00	30.00	40.00	136
LT Debt, Non Current	-100.0%	-	466	395	400	285	40.00	-	-	1,648	2,079	1,612	1,577	1,482	2,204	2,192	2,221	2,513	2,284	4,002	4,078	4,037
Shareholder's Equity	-3.1%	3,311	3,418	3,440	3,451	3,445	3,448	3,408	3,491	4,644	4,661	4,631	4,352	4,291	3,588	3,457	3,396	3,338	3,490	3,133	3,256	3,742
Retained Earnings	-13.3%	470	542	540	542	552	576	614	681	604	589	591	565	536	517	484	471	479	480	496	486	955
Additional Paid-In Capital	0.1%	2,903	2,901	2,953	2,944	2,934	2,926	2,909	2,897	4,555	4,544	4,528	4,225	4,202	3,478	3,470	3,463	3,454	3,446	3,435	3,428	3,421
Shares Outstanding	0.4%	55.00	55.00	55.00	55.00	54.00	54.00	54.00	54.00	54.00	52.00	90.00	83.00	45.00	-	-	-	-	-	-	-	-
Minority Interest	4.6%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	44.00	44.00	44.00	44.00	44.00	44.00	45.00	44.00	47.00	48.00	151	162	164
Float	-	-	-	-	3,478	-	-	-	2,683	-	-	-	5,867	-	-	-	2,823	-	-	-	2,650	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-152.8%	-36,156	68,415	31,013	28,103	7,457	-35,958	19,410	-24,890	-14,423	96,216	97,131	78,370	84,382	128,802	79,919	36,985	56,229	65,199	55,317	82,720	-72,288
Share Based Compensation	-85.0%	1,245	8,307	8,777	9,375	7,606	11,156	8,006	9,936	9,857	9,115	8,973	9,455	7,807	7,269	6,957	8,561	6,124	4,955	5,836	5,931	5,238
Cashflow From Investing	-1243.8%	-797,842	-59,372	-17,107	-131,603	-34,385	-37,076	-59,139	-45,007	-35,166	-26,828	-21,548	-144,088	-128,012	-90,948	-31,153	-15,723	-37,255	1,596,929	-21,151	-37,627	-3,170,908
Cashflow From Financing	30898.2%	864,540	2,789	-13,703	114,213	24,498	41,628	-456	-495,480	-10,819	473,069	40,154	-635,969	707,652	-6,073	-48,165	-322,550	245,137	-1,721,400	-88,128	-60,004	3,239,026
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	32.00	971	-	-	-	-	-	-46,543	366	92,721

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENOV Income Statement

2024-03-29

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 516,266	$ 406,151
Cost of sales	218,370	171,086
Gross profit	297,896	235,065
Selling, general and administrative expense	255,691	207,165
Research and development expense	23,377	18,193
Amortization of acquired intangibles	40,931	32,040
Restructuring and other charges	12,911	2,635
Operating loss	(35,014)	(24,968)
Interest expense, net	19,996	5,652
Other (income) expense, net	24,235	(661)
Loss from continuing operations before income taxes	(79,245)	(29,959)
Income tax benefit	(7,404)	(7,113)
Net loss from continuing operations	(71,841)	(22,846)
Loss from discontinued operations, net of taxes	0	(312)
Net loss	(71,841)	(23,158)
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes	157	192
Net loss attributable to Enovis Corporation	$ (71,998)	$ (23,350)
Net loss per share - basic and diluted
Net income (loss) per share, continuing operations, basic (in usd per share)	$ (1.32)	$ (0.42)
Net income (loss) per share, continuing operations, diluted (in usd per share)	(1.32)	(0.42)
Net income (loss) per share, discontinued operations, basic (in usd per share)	0	(0.01)
Net income (loss) per share, discontinued operations, diluted (in usd per share)	0	(0.01)
Net income (loss) per share, consolidated, basic (in usd per share)	(1.32)	(0.43)
Net income (loss) per share, consolidated, diluted (in usd per share)	$ (1.32)	$ (0.43)

ENOV Balance Sheet

2024-03-29

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 29, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 66,267	$ 36,191
Trade receivable, less allowance for credit losses	381,053	291,483
Inventories, net	586,002	468,832
Prepaid expenses	36,033	28,901
Other current assets	81,364	71,112
Total current assets	1,150,719	896,519
Property, plant and equipment, net	345,701	270,798
Goodwill	2,414,611	2,060,893
Intangible assets, net	1,408,310	1,127,363
Lease asset - right of use	70,146	63,506
Other assets	89,194	90,255
Total assets	5,478,681	4,509,334
LIABILITIES AND EQUITY
Current portion of long-term debt	20,101	0
Accounts payable	155,748	132,475
Accrued liabilities	373,283	237,132
Total current liabilities	549,132	369,607
Long-term debt, less current portion	1,318,463	466,164
Non-current lease liability	51,190	48,684
Other liabilities	249,054	204,178
Total liabilities	2,167,839	1,088,633
Equity:
Common stock, $0.001 par value; 133,333,333 shares authorized; 54,840,581 and 54,597,142 shares issued and outstanding as of March 29, 2024 and December 31, 2023, respectively	55	55
Additional paid-in capital	2,903,277	2,900,747
Retained earnings	470,473	542,471
Accumulated other comprehensive loss	(65,378)	(24,881)
Total Enovis Corporation equity	3,308,427	3,418,392
Noncontrolling interest	2,415	2,309
Total equity	3,310,842	3,420,701
Total liabilities and equity	$ 5,478,681	$ 4,509,334

About Enovis Corporation

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

CEO	Mr. Matthew L. Trerotola
WEBSITE	enovis.com
INDUSTRY	Apparel Manufacturing
EMPLOYEES	6800

Enovis Corporation Frequently Asked Questions

What is the ticker symbol for Enovis Corporation? What does ENOV stand for in stocks?

ENOV is the stock ticker symbol of Enovis Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enovis Corporation (ENOV)?

As of Fri May 17 2024, market cap of Enovis Corporation is 2.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENOV stock?

You can check ENOV's fair value in chart for subscribers.

What is the fair value of ENOV stock?

You can check ENOV's fair value in chart for subscribers. The fair value of Enovis Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enovis Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enovis Corporation a good stock to buy?

The fair value guage provides a quick view whether ENOV is over valued or under valued. Whether Enovis Corporation is cheap or expensive depends on the assumptions which impact Enovis Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENOV.

What is Enovis Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ENOV's PE ratio (Price to Earnings) is -35.12 and Price to Sales (PS) ratio is 1.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENOV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enovis Corporation's stock?

In the past 10 years, Enovis Corporation has provided -0.03 (multiply by 100 for percentage) rate of return.